NCT06388200Phase 3Active not recruiting

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Study sponsor: Ocugen

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-02-12Estimated
Enrollment · participants140Actual
Source updated2026-07-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA. After: Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 150 participants (planned). After: 140 participants (actual).

Primary completion date changed

Before: 31 Dec 2026. After: 12 Feb 2027.

Check registry source

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview